Global Male Infertility Market to Reach $5780.03 Million by 2030

According to Triton Market Research's report, the global male infertility market, which garnered $3982.19 million in 2022, is projected to advance with a CAGR of 4.81% during the forecast period.

A recent study by Triton Market Research titled Global Male Infertility Market is sectioned by Treatment (Medications, Assisted Reproductive Technology and Surgery), Test Type (Sperm Penetration Assay, Sperm Agglutination, Oxidative Stress Analysis, Microscopic Examination, Computer-Assisted Semen Analysis, DNA Fragmentation Technique, Other Test Types), and Regional Outlook (North America, Latin America, Asia-Pacific, Middle East and Africa, Europe).

Read the Market Summary Here: https://www.tritonmarketresearch.com/reports/male-infertility-market#report-overview

Male infertility is typically linked to issues related to sperm production or delivery. These include low sperm production, abnormal sperm function, and blockages that hinder sperm delivery. Additionally, factors such as illnesses, injuries, chronic health conditions, and other ailments may contribute to male infertility.

Request a Free Sample of the Global Male Infertility Market Report @ https://www.tritonmarketresearch.com/reports/male-infertility-market#request-free-sample

As per Triton's report, the global male infertility market is estimated to acquire revenue worth $5780.03 million by 2030, growing at a CAGR of 4.81% during the forecast period 2023-2030.

The rising incidence of infertility and the adoption of assisted reproductive technology worldwide are significant factors boosting the global male infertility market's growth. Male infertility is a global health concern primarily associated with hormonal imbalance or sperm movement obstruction, leading to low sperm quantity and poor quality. According to industry sources, infertility affects 8-12% of couples globally, with male factors being the primary or contributing cause in about 50% of cases. In this regard, assisted reproductive technology (ART) encompasses various fertility treatments that effectively solve male infertility issues like low sperm count, abnormal sperm quality, and poor motility.

However, the elevated cost of treatments, including ART, hampers the overall development of the male infertility market.

The male infertility market is broadly sectioned into treatment and test type. The treatment section includes medications and assisted reproductive technology and surgery. The test type further comprises sperm penetration assay, sperm agglutination, oxidative stress analysis, microscopic examination, computer-assisted semen analysis, DNA fragmentation technique, and other test types.

Globally, Europe dominates with a majority share in the male infertility market. The region's substantial growth is supported by the increased adoption of affordable therapies and devices, the growing use of assisted reproductive technologies, and the availability of reimbursement coverages. Moreover, the presence of major market players contributes to the market's growth. Some prominent companies operating in the region include Bayer AG, Merck Serono, Endo International plc, and Halotech DNA SL. The ongoing research and development investments, coupled with a sizable patient base and approvals from the European Medicines Agency (EMA), are expected to further bolster the market's growth in Europe.

Laboratory Corporation of America Holdings, Halotech DNA, EMD Serono Inc, Sanofi SA, Zydus Lifesciences Limited, Endo International Plc, Bayer AG, Vitrolife, Aytu BioPharma, and CinnaGen Co are leading companies in the male infertility market.

Purchase this report @ https://www.tritonmarketresearch.com/reports/male-infertility-market#purchase-option

Question & Answer: Global Male Infertility Market

Question 1: What factors are boosting the global male infertility market's growth?
Answer: The rising incidence of infertility and the adoption of assisted reproductive technology worldwide are significant factors boosting the global male infertility market's growth. Male infertility is a global health concern primarily associated with hormonal imbalance or sperm movement obstruction, leading to low sperm quantity and poor quality. According to industry sources, infertility affects 8-12% of couples globally, with male factors being the primary or contributing cause in about 50% of cases. In this regard, assisted reproductive technology (ART) encompasses various fertility treatments that effectively solve male infertility issues like low sperm count, abnormal sperm quality, and poor motility.

Question 2: What factor hampers the overall development of the male infertility market?
Answer: The elevated cost of treatments, including ART, hampers the overall development of the male infertility market.

Question 3: Which region dominates the male infertility market?
Answer: Globally, Europe dominates with a majority share in the male infertility market. The region's substantial growth is supported by the increased adoption of affordable therapies and devices, the growing use of assisted reproductive technologies, and the availability of reimbursement coverages. Moreover, the presence of major market players contributes to the market's growth. Some prominent companies operating in the region include Bayer AG, Merck Serono, Endo International plc, and Halotech DNA SL. The ongoing research and development investments, coupled with a sizable patient base and approvals from the European Medicines Agency (EMA), are expected to further bolster the market's growth in Europe.

Question 4: Which are the leading companies in the male infertility market?
Answer: Laboratory Corporation of America Holdings, Halotech DNA, EMD Serono Inc, Sanofi SA, Zydus Lifesciences Limited, Endo International Plc, Bayer AG, Vitrolife, Aytu BioPharma, and CinnaGen Co are leading companies in the male infertility market.

Related Report:

GLOBAL AMNIOTIC MEMBRANE MARKET- https://www.tritonmarketresearch.com/reports/amniotic-membrane-market

As per Triton's report, the global amniotic membrane market is expected to advance with a CAGR of 7.01% during the forecast period 2022-2028.

Factors such as growing awareness about wound care treatment, research on stem cells and regenerative medicine, and incidents of traumatic wounds fuel the amniotic membrane market's expansion.

GLOBAL HORMONE REPLACEMENT THERAPY MARKET-
https://www.tritonmarketresearch.com/reports/hormone-replacement-therapy-market

Based on Triton Market Research's report, the global hormone replacement market is likely to rise with a CAGR of 7.75% over the forecast period 2021-2028.

Factors such as an increase in hormonal disorder cases and new product launches widen the scope and growth of the hormone replacement therapy market. However, high treatment costs and concerns over adverse reactions limit the studied market's expansion globally.

Triton Market Research
196, wards wharf approach
London E16 2EQ
Phone: +44 7441 911839
Email: sales@tritonmarketresearch.com
Website: https://www.tritonmarketresearch.com/

Triton is a leading market research company providing clients with the best online market research data reports. Our offerings include syndicated market insights, customized research reports, and cost-effective consulting services for constructive decision-making.

This release was published on openPR.